ClinicalTrials.gg
CompletedNCT04845178Updated Sep 4, 2024

Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

A Phase 2 interventional study of ABP-450 and Placebo in Migraine, sponsored by AEON Biopharma, Inc.. Completed at 62 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-04.

Sponsored by AEON Biopharma, Inc. · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Jun 2024, 2 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
797
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 696 studies in Migraine Disorders with a site in United States — 93 open to participants now, 115 under way, 27 of them phase 3. Migraine Disorders · United States.

Enrollment
58th of 609
797 · median 78
Started
2021
with 41 others
Phase 2
90 of 696
7 open now
Registered
494th of 696
by date

Among the 696 studies in Migraine Disorders with a site in United States, this one is the 58th largest by enrollment of the 609 interventional ones that give a count, is one of 42 that started in 2021, is one of 90 in phase 2, and was the 494th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

93 of the 696 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:

88 more — sign in →

All 93 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 696 studies in Migraine Disorders with a site in United States, or all of them as a file.
02

Study summary

This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month. The study will enroll 765 patients across approximately 64 sites in the United States, Canada and Australia. Study subjects will be divided evenly across a low dose group, a high dose group and a placebo group. All patients will receive two treatment cycles of ABP-450 or placebo utilizing the Company's novel injection paradigm.

Read the detailed description

The Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month. The study will enroll 765 patients across approximately 64 sites in the United States, Canada and Australia. Study subjects will be divided evenly across a low dose of ABP-450 group, a high dose of ABP-450 group, and a placebo group. All patients will receive two treatment cycles utilizing the Company's novel treatment paradigm involving fewer injections than the current botulinum toxin treatment option for chronic migraine.

03

Conditions studied

  • Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient can understand the ICF, provides signed ICF and patient privacy information (eg, Authorization for Use and Release of Health and Research Study Information) before initiating any study-specific procedure, and agrees to comply with protocol requirements.
  2. Male or female patients 18 years or older of age (no upper age limit) at the time of signing the .
  3. Patient has at least a 1-year history of episodic migraine (with or without aura) or chronic migraine (with or without aura) according to the ICHD-3 (2018) definition and diagnostic criteria.
  4. Age of the patient at the time of migraine onset \<50 years.
  5. History of, on average ≥6 migraine or probable migraine days per month in the 3 months prior to Screening.
  6. Patient is on a stable dose of medications, if any, as recommended by the patient's health care practitioner, used for acute treatment of migraine for at least 3 months prior to Screening. Patient is not taking any migraine prophylactic treatment prohibited per protocol or if on prophylactic treatment has washed out.
  7. A Woman of Child Bearing Potential () must be willing and able to use a medically acceptable and effective method of as determined by the investigator, during the entire study.
  8. A WOCBP must have a negative pregnancy test at Screening.
  9. Patient is able to read, understand, and complete the eDiary.
  10. Patient is willing and able to adhere to the study assessments, visit schedules, and prohibitions, as described in this protocol.

Exclusion criteria

Exclusion Criteria:

Medical Conditions

  1. History of migraine accompanied by diplopia or decreased level of consciousness, or retinal migraine.
  2. Current diagnosis of chronic tension-type headache, new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or cranial neuropathy.
  3. Confounding and pain syndromes (eg, fibromyalgia, chronic low back pain, complex regional pain syndromes) as evaluated by the investigator.
  4. Diagnosis of myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other significant neuromuscular disease that might interfere with the study.
  5. Psychiatric conditions that are uncontrolled and/or untreated, including conditions that are not controlled for a minimum of 6 months prior to Screening as evaluated by the investigator. Patients with a lifetime history of psychosis, mania, or dementia are excluded.
  6. History of addiction, including alcohol or drugs of abuse, within 6 months prior to Screening.
  7. (HBsAg positive) or (ie, detectable HCV RNA) virus infection.

    Note: Patients with a prior history of treated hepatitis B virus infection who are antigen negative or patients with a prior history of treated HCV infection who are HCV RNA undetectable may be considered after consultation with the study medical monitor.

  8. Any infection or clinically significant skin problem in any of the injection sites.
  9. Have been injected with anesthesia or in the targeted muscles during the 30 days immediately prior to initiation of the Baseline period.
  10. Any medical condition (including but not limited to viral or other active infections) that, in the opinion of the investigator, classifies the patient as unsuitable for participation in the study or patients who do not seem to be in good general health at the time of Screening, and prior to any study drug administration.

    Note: Patients will not routinely be tested for COVID-19 during the study. Patients presenting with fever or who are symptomatic for COVID-19 will be required to be tested and treated through their general practitioner.

    Other Diagnostic Assessments

  11. Significant risk of self-harm based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigator; patients must be excluded if they report suicidal ideation with intent, with or without a plan (ie, Type 4 or 5 on the C-SSRS) in the past 6 months or report suicidal behavior in the past 6 months prior to Screening.
  12. ≥38 kg/m2 at Screening.

    Prior/Concomitant Medications and Treatments

  13. Use of opioids or barbiturates >2 days per month in the 3 months prior to Screening.
  14. Use of CBD or other types of cannabinoids in the 3 months prior to Screening and throughout the study.
  15. Any use of botulinum toxin for migraine or any other medical reasons within 4 months prior to Screening and during the Screening and Baseline periods and at or above the shoulders at any time during the study.
  16. Any monoclonal antibody CGRP inhibitor treatment (within or outside of a clinical study) within 6 months prior to Screening and throughout the study.
  17. Any orally administered non-peptide CGRP antagonists (within or outside of a clinical study) within 4 weeks prior to the Baseline period and throughout the study.
  18. Use of devices for the treatment of migraine (ie, non-invasive neuromodulation therapies including but not limited to non-invasive nerve stimulation [gammaCore], transcranial magnetic stimulation [Cefaly], external trigeminal nerve stimulation, transcutaneous electrical nerve stimulation, and peripheral neuroelectrical stimulation) during Screening and throughout the study.
  19. Any other treatments or therapies (eg, acupuncture in head and neck region, cranial traction, nociceptive trigeminal inhibition, occipital nerve block treatments, and dental splints for headache) to the head, neck, or shoulder regions during Screening and throughout the study that, in the opinion of the investigator, would interfere with the investigational study drug.
  20. History of inadequate response to 3 classes of medications (which have different mechanisms of action) prescribed for the prevention of migraine, excluding CGRP therapies.
  21. History of to human serum albumin, sucrose, or botulinum toxin type A or a positive test for botulinum toxin type A antibody.

    Prior/Concurrent Clinical Study Experience

  22. Participation in another interventional study within 6 months prior to Screening and throughout the study.
  23. Female patients planning on becoming pregnant during the course of the study and/or lactating/breastfeeding.
  24. Patient has donated or lost a significant volume (>450 mL) of blood or plasma within 30 days of screening.
  25. Patient is an employee or family member of the investigator, study site personnel, PPD, or AEON.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
797 participants (actual)

Study arms

  • Experimental
    ABP-450 - Low Dose

    ABP-450 Low Dose - intramuscular injections into specified muscles.

    Drug: ABP-450

  • Experimental
    ABP-450 - High Dose

    ABP-450 High Dose - intramuscular injections into specified muscles.

    Drug: ABP-450

  • Placebo comparator
    Placebo

    Placebo (0.9% saline, sterile, unpreserved, USP/Ph.Eur) intramuscular injections into specified muscles.

    Drug: Placebo

Interventions

  • ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.

    Also known as: prabotulinumtoxinA

  • DrugPlacebo

    0.9% sodium chloride, sterile, unpreserved, USP/PhEur

    Also known as: 0.9% sodium chloride, saline

06

What researchers measure

Primary outcomes

  1. Change in Monthly Migraine Days

    The primary efficacy endpoint will be the change in mean Monthly Migraine Days (MMD) from the 4-week Baseline period to Weeks 21 to 24 Treatment period.

    Time frame: Baseline to Weeks 21 to 24 Treatment period.

  2. Incidence of Treatment Emergent Adverse Events

    The primary safety endpoint will be the incidence of TEAEs throughout the study when dosed with placebo, ABP-450 (low dose), or ABP-450 (high dose).

    Time frame: Baseline to Week 28 - End of Study.

Secondary outcomes

  1. Percentage of Patients with Reduction in Mean Migraine Days (MMD)

    Percentage of patients with a reduction from Baseline of ≥ 50 percent, ≥ 75 percent and 100% percent in average number of MMD will be assessed by Treatment Group.

    Time frame: Baseline to Week 28 - End of Study.

  2. Mean change in Monthly Migraine Days (MMD)

    Overall mean change from Baseline in the number of MMD will be assessed by Treatment Group.

    Time frame: Baseline to Week 28 - End of Study.

  3. Mean change in Monthly Migraine Days (MMD) requiring medications for acute treatment of migraine or headaches

    Overall mean change from Baseline in number of MMD requiring migraine specific medication and non-specific medications for the acute treatment of migraine or headache will be assessed by Treatment Group.

    Time frame: Baseline to Week 28 - End of Study.

  4. Mean change in Headache Hours

    Overall mean change from Baseline in headache (either moderate or severe) hours will be assessed by Treatment Group.

    Time frame: Baseline to Week 28 - End of Study.

  5. Mean Change in Monthly Headache Days

    Overall mean change from Baseline in monthly headache days will be assessed by Treatment Group.

    Time frame: Baseline to Week 28 - End of Study.

  6. Mean change of Migraine-Specific-Quality of Life (MSQ) Domains

    The Mean Change in Migraine-Specific-Quality of Life (MSQ), a 14-item assessment, with each item rated on a 6-point scale (ranging from "none of the time" to "all of the time") with higher scores indicating better quality of life will be assessed by Treatment Group.

    Time frame: Baseline to Week 28 - End of Study.

  7. Percentage of Patients with Reduction in Migraine Physical Function Impact Diary (MPFID)

    Percentage of patients with a reduction from Baseline in the impact on Migraine Physical Function Impact Diary (MPFID) will be assessed by Treatment Group.

    Time frame: Baseline to Week 28 - End of Study.

  8. Suicidality by Columbia-Suicide Severity Rating Scale (C-SSRS)

    Percentage of patients with Suicidal Ideation and Behaviors will be assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS).

    Time frame: Baseline to Week 28 - End of Study.

  9. Development of Anti-Drug Antibodies (ADA) to ABP-450

    Percentage of patients developing Anti-Drug Antibodies to ABP-450 antibodies (binding and if positive, neutralizing) will be assessed.

    Time frame: Baseline to Week 28 - End of Study.

Other outcomes

  1. Mean Change in Patient Global Impression of Change (PGI-C) Score

    The Mean change in the subject's assessment of the change in clinical status since the start of treatment measured by the Patients' Global Impression of Change (PGI-C) Scale will be assessed by Treatment Group.

    Time frame: Baseline to Week 28 - End of Study.

  2. Mean Change in Patient Global Impression of Severity (PGI-S) Score

    The Mean change in the subject's assessment of the severity of their condition since the start of treatment measured by the Patients' Global Impression of Severity (PGI-S) Scale will be assessed by Treatment Group.

    Time frame: Baseline to Week 28 - End of Study.

  3. Mean Change in MIgraine Disability Assessment Score (MIDAS) Total Score

    The Mean Change in the Migraine Disability Assessment Scale (MIDAS) between Baseline and End of Treatment assessed by Treatment Group. MIDAS is a 5-item self-administered questionnaire. The 5 items sum to a total MIDAS score of 0 to 155. A higher score indicates greater headache-related disability (worse score).

    Time frame: Baseline to Week 28 - End of Study.

  4. Percentage of Patients with Reduction in the Physical Impairment Domaine Score of the Migraine Physical Function Impact Diary (MPFID)

    Percentage of patients with a reduction from Baseline on Physical Impairment Domain Score measured by Migraine Physical Function Impact Diary (MPFID) assessed by Treatment Group.

    Time frame: Baseline to Week 28 - End of Study.

07

Study locations

62 sites
  • MDFirst Research
    Chandler, Arizona 85226, United States
  • Elite Clinical Studies, LLC
    Phoenix, Arizona 85018, United States
  • Arizona Neuroscience Research
    Phoenix, Arizona 85032, United States
  • Clinical Research Consortium Arizona
    Tempe, Arizona 85281, United States
  • Axiom Research LLC
    Colton, California 92324, United States
  • Velocity Research San Diego
    La Mesa, California 91942, United States
  • Collaborative Neuroscience Research
    Long Beach, California 90806, United States
  • Los Angeles Headache Center
    Los Angeles, California 90067, United States
  • Anderson Clinical Research
    Redlands, California 92374, United States
  • Artemis Institute For Clinical Research LLC - San Diego - ClinEdge - PPDS
    San Diego, California 92103, United States
  • Delta Waves LLC - Hunt - PPDS
    Colorado Springs, Colorado 80918, United States
  • Paradigm Clinical Research Centers
    Wheat Ridge, Colorado 80033, United States
  • New England Institute for Neurology and Headache
    Stamford, Connecticut 06905, United States
  • Quality Research of South Florida
    Hialeah, Florida 33016, United States
  • Sandhill Research, LLC
    Lake Mary, Florida 32746, United States
  • Canvas Clinical Research
    Lake Worth, Florida 33467, United States
  • BioMed Research Institute, INC
    Miami, Florida 33126, United States
  • Medical Research Center, LLC
    Miami, Florida 33144, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Innovation Medical Research Center
    Palmetto Bay, Florida 33157, United States
  • Clinical Research of Central Florida - ClinEdge - PPDS
    Winter Haven, Florida 33810, United States
  • NeuroTrials Research Inc. - Clinedge - PPDS
    Atlanta, Georgia 30328, United States
  • Drug Studies America, Inc
    Marietta, Georgia 30060, United States
  • Velocity Clinical Research - Boise - ERN - PPDS
    Meridian, Idaho 83642, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607, United States
  • Kansas Institute of Research, LLC
    Overland Park, Kansas 66211, United States
  • Crescent City Headache and Neurology Center
    Chalmette, Louisiana 70043, United States
  • Tandem Clinical Research
    Marrero, Louisiana 70072, United States
  • Boston Clinical Trials Inc
    Boston, Massachusetts 02131, United States
  • MedVadis Research
    Waltham, Massachusetts 02451, United States
  • Quest Research Institute - Hunt - PPDS
    Farmington Hills, Michigan 40825, United States
  • Henry Ford Allegiance Neurology
    Jackson, Michigan 49201, United States
  • StudyMetrix Research, LLC
    Saint Peters, Missouri 63303, United States
  • Clinvest Research LLC
    Springfield, Missouri 65810, United States
  • Barrett Clinic, P.C. - Clinedge - PPDS
    La Vista, Nebraska 68128, United States
  • Quality Clinical Research
    Omaha, Nebraska 68114, United States
  • Wake Research - CRCN, LLC
    Las Vegas, Nevada 89118, United States
  • Hassman Research Institute - ClinEdge - PPDS
    Berlin, New Jersey 08009, United States
  • Albuquerque Clinical Trials Inc
    Albuquerque, New Mexico 87102, United States
  • Dent Neurologic Institute
    Amherst, New York 14226, United States
  • New York Neurology Associates
    New York, New York 10003, United States
  • Upstate Clinical Research Associates LLC
    Williamsville, New York 14221, United States
  • Dayton Center for Neurological Disorders
    Centerville, Ohio 45459, United States
  • META Medical Research Institute, LLC
    Dayton, Ohio 45432, United States
  • Centricity Research Dublin Multispecialty
    Dublin, Ohio 43016, United States
  • The Orthopedic Foundation
    New Albany, Ohio 43054, United States
  • Thomas Jefferson University, Jefferson Headache Center
    Philadelphia, Pennsylvania 19107, United States
  • Preferred Primary Care Physicians
    Pittsburgh, Pennsylvania 15236, United States
  • WR-ClinSearch
    Chattanooga, Tennessee 37421, United States
  • Bryant Research Group
    Nashville, Tennessee 37203, United States
  • DCT - Baxter LLC dba Discovery Clinical Trials
    Dallas, Texas 75225, United States
  • Mercury Clinical Research Incorporated
    Sugar Land, Texas 77478, United States
  • Aspen Clinical Research LLC - Clinedge - PPDS
    Orem, Utah 84058, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98004, United States
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
  • Grampians Health
    Ballarat, Victoria 3350, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
  • Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • CARe Clinic
    Red Deer, Alberta T4P 1K4, Canada
  • True North Clinical Research
    Halifax, Nova Scotia B3S 1N2, Canada
  • Bluewater Clinical Research Group
    Sarnia, Ontario N7T 4X3, Canada
  • Diex Recherche Québec
    Québec, Quebec G1N 4V3, Canada
08

References and documents

Individual participant data

Plan to share: No — Individual Participant Data collected during the trial, after deidentification may be shared following review of the clinical study report by the FDA review division and if a decision is made to publish the results in an publication outside posting the results in clinicaltrials.gov

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Jun 2024, 39 months.

Of 43 industry-sponsored phase 2 interventional studies under Migraine Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 39 months is above that.

Counting every sponsor, half of 73 studies reached it within 15 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2021
First posted
Apr 14, 2021
StartActual
Mar 1, 2021
Primary completionActual
Jun 19, 2024
CompletionActual
Aug 6, 2024
Last update
Sep 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04845178
Lead sponsor
AEON Biopharma, Inc.
Collaborators
PPD DEVELOPMENT, LP
Responsible party
Sponsor
First posted
Apr 14, 2021
Start date
Mar 1, 2021
Primary completion
Jun 19, 2024
Completion
Aug 6, 2024
Last update
Sep 4, 2024

Study contacts

Richard B Lipton, MD
principal investigator · Albert Einstein College of Medicine
Stewart J Tepper, MD
principal investigator · Dartmouth-Hitchcock Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prabotulinumtoxin A

Start the discussion